Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer. - Wikidata - wikimedia - TriplyDB

Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer.

Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer.

http://www.wikidata.org/entity/Q37520289

about

Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives.Applying nanotherapeutics to improve chemoradiotherapy treatment for cancer.

P2860

Q33829321-C94B4893-74F1-4CDD-89A1-19FA266BE834 Q48270428-5433E645-AF43-4E1B-B0C2-6B7E1C257A7C Q50499549-1FF249CB-14D6-4608-AE73-3C6A31175B45

P2860

Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer.

http://www.wikidata.org/entity/Q37520289

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Radiation-enhanced therapeutic ...... triple negative breast cancer.

@en

Radiation-enhanced therapeutic ...... triple negative breast cancer.

@nl

type

label

Radiation-enhanced therapeutic ...... triple negative breast cancer.

@en

Radiation-enhanced therapeutic ...... triple negative breast cancer.

@nl

prefLabel

Radiation-enhanced therapeutic ...... triple negative breast cancer.

@en

Radiation-enhanced therapeutic ...... triple negative breast cancer.

@nl

P1433

Q37520289-CC7FEFE8-032D-4238-A03C-9E071D82153F

P1476

Q37520289-63756473-2F03-4D03-B307-9AD6FCC1BD93

P2093

Q37520289-0C1235B0-F9F2-4E1A-833B-952A0B9987D1

Q37520289-2E268A89-3F15-436F-807D-494D3F7CBF11

Q37520289-348CDD24-5C22-495A-ADB2-B079F03B67F4

Q37520289-364616B7-0776-4A78-9546-FB30DC4386DE

Q37520289-3AF0AE25-83DD-45E1-BBC2-FDD79874A85E

Q37520289-47DE11AC-104F-4DB6-8EC7-D68B5B27DF03

Q37520289-9444F494-CDFA-44F8-A986-5FC45CC4A3F4

Q37520289-E0FE79A9-3BDD-4F6A-B0DC-87977DD6719A

Q37520289-E66A449C-5174-490D-957A-E2C473C00896

Q37520289-E798B425-7A78-4605-9D44-0B29935BFB10

P2860

Q37520289-087DA983-4C0D-4AAF-A312-FD72B3E4F0F3

Q37520289-0A3FCA08-E128-442B-ACE2-66269666851C

Q37520289-0AAFE710-F060-41B2-8AD1-F72BF2A9A63E

Q37520289-0DAA18AB-EDF4-4516-B1B0-45340A2BF965

Q37520289-1004782E-7890-4AD3-A040-BEEB84F19850

Q37520289-128915BD-9869-4B61-8E34-6DDF7311373D

Q37520289-17CC776A-7485-49CE-B302-D79DC15964E3

Q37520289-1F75CA43-DABC-491A-AC62-E1ECC6F9A174

Q37520289-20FC082A-ACAD-41E2-BA93-1E1BF9C72DB9

Q37520289-22C18B51-5A75-4024-A891-7B46EC982DBF

P304

Q37520289-7B7690D2-AA1E-4FBB-B9B2-D22A63229EA8

P31

Q37520289-57339D9F-AFBD-4BBC-8074-8EDC414B317D

P356

Q37520289-4FA05A72-13F1-47CE-AEBA-1A0072B5C044

P407

Q37520289-363D610B-2F19-4443-823E-C7D6BAD24819

P433

Q37520289-6EB82759-FDC7-4A18-A00D-222C6B2B4A8C

P478

Q37520289-6A06A6F1-E2B2-481E-AB4C-C4832406E728

P50

Q37520289-F089AD0F-548A-4DF1-B172-2A273EE09011

P577

Q37520289-5EC7ECB6-765F-4438-A05C-EE8735CA38FF

P698

Q37520289-21DF92E2-9F13-4BB1-8EE7-BAEB21BB0EC5

P932

Q37520289-9796A929-9836-48C7-9BC1-0906A4670397

P356

ONCOTARGET.9490

P1433

P1476

Radiation-enhanced therapeutic ...... triple negative breast cancer.

@en

P2093

Amar Jyoti

http://www.w3.org/2001/XMLSchema#string

B Mark Evers

http://www.w3.org/2001/XMLSchema#string

Elden P Swindell

http://www.w3.org/2001/XMLSchema#string

Heidi L Weiss

http://www.w3.org/2001/XMLSchema#string

Jonathan M Feddock

http://www.w3.org/2001/XMLSchema#string

Meenakshi Upreti

http://www.w3.org/2001/XMLSchema#string

Pallavi Sethi

http://www.w3.org/2001/XMLSchema#string

Ryan Chan

http://www.w3.org/2001/XMLSchema#string

Sara E Johnson

http://www.w3.org/2001/XMLSchema#string

Thomas V O'Halloran

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Regulation of Mutant p53 Protein Expression

The omics of triple-negative breast cancers

Molecular portraits of human breast tumours

Whole-genome analysis informs breast cancer response to aromatase inhibition

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Cellular processing of platinum anticancer drugs

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Designed beta-sheet peptides that inhibit proliferation and induce apoptosis in endothelial cells.

P304

41559-41574

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.9490

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27223428

http://www.w3.org/2001/XMLSchema#string

P932

5173078

http://www.w3.org/2001/XMLSchema#string